

ASX Announcement

US Pharma Veteran Guy Breitenbucher joins Race's Scientific Advisory Board

- Highly experienced medicinal chemist, Dr Guy Breitenbucher, appointed to Race's Scientific Advisory Board
- Outstanding drug discovery & clinical development leader with over 26 years of US pharma industry experience
- Will help guide Race's preclinical and clinical drug and formulation development programs.

18 May 2022 – Race Oncology Limited ("Race") is pleased to advise that it has appointed Dr James Guy Breitenbucher to its Scientific Advisory Board (SAB).

Dr Breitenbucher brings to Race an extensive drug discovery and clinical development history, having spent more than 26 years in scientific leadership positions at a range of large and small pharmaceutical companies, including Johnson & Johnson Pharmaceuticals, Convelo Therapeutics, Libra Therapeutics, Dart Neuroscience, Axys Pharmaceuticals, and Bristol Myers Squibb.

Dr Breitenbucher is an exceedingly successful drug discovery and development researcher, having advanced numerous pharmaceutical projects from concept to the clinic. He is highly skilled in solving complex drug discovery problems, including those surrounding formulations, DMPK, structure biology, pharmacology, biomarkers, IP and safety.

While VP of Chemistry at Convelo Therapeutics, he led a major industrial research partnership with Genentech¹. At Johnson & Johnson, Guy led multiple pain and CNS drug development programs and delivered 11 compounds into the J&J clinical pipeline, 3 of which are currently in clinical development.

Guy has published more than 59 peer reviewed scientific papers, is a named inventor on 39 patents and has given numerous invited scientific presentations at international conferences. His deep scientific and pharmaceutical industry knowledge will be exceptionally valuable to Race as it advances the development of improved Zantrene[®] formulations and explores the development of new m⁶A RNA focused molecules.

Dr Breitenbucher joins eminent m⁶A RNA researcher and discoverer of Zantrene's role as a potent FTO inhibitor, Professor Jianjun Chen of the City of Hope Hospital (USA), on the Race SAB (ASX Announcement: 16 April 2021).

Race CEO Mr Phillip Lynch said *"We are extremely pleased to have Guy joining the Race SAB. As we move our R&D and clinical programs forward, it's imperative that we access the very best advice available. Guy will provide Race with a level of drug development knowledge*

and experience rarely found in Australia and his appointment is a significant enabler for our company and its development plans.”

Race CSO Daniel Tillett said *“Attracting an experienced drug developer of Guy’s stature to our SAB is a massive win for Race. Bringing a new drug to market is never easy, to succeed you need to involve the best of the best in the industry. I am looking forward to working closely with Guy and drawing on his experience and insights as we advance Zantrene through its clinical, regulatory and commercial journey.”*

Dr Guy Breitenbucher said *“I am honored to be able to play a role in Race Oncology’s mission to bring breakthrough cancer therapeutics to the patients who need them. I look forward to working with the highly professional team at Race to further their life-saving work.”*

-ENDS-

About Guy Breitenbucher

James Guy Breitenbucher, Ph.D. is Vice President of Chemistry at Libra Therapeutics, a San Diego-based pharm company focused on developing novel, disease-modifying drugs for neurodegenerative diseases. Prior to joining Libra in 2020, Dr. Breitenbucher was Vice President of Chemistry at Convelo Therapeutics (Cleveland, OH, USA, 2018-20), Senior Director of Discovery Chemistry at Dart Neuroscience (San Diego, CA, USA, 2010-2018), Department Head/Research Fellow in Pain Discovery Chemistry (2003-2010) and Team Leader: Hit-to-Lead Chemistry (1999-2003) at Johnson and Johnson Pharmaceutical R&D (San Diego, CA, USA), Scientist at Axys Pharmaceuticals (later Celera, South San Francisco, CA, USA, 1996-1999) and Research Scientist at Bristol Myers Squibb Co. (Wallingford, CT, USA, 1995-1996).

Dr Breitenbucher received his PhD in organic chemistry (synthetic chemistry methodology and alkaloid total synthesis) from the University of California, Riverside (1993) under the supervision of Professor Steven Angle. He completed a postdoctoral research fellowship in natural products total synthesis with Professor Clayton Heathcock at the University of California, Berkeley (1993-1995).

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines



and proteasome inhibitors to improve their ability to target breast cancer. Race is evaluating this discovery.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene.

Learn more at www.raceoncology.com

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au